Business Context and Reporting Period
This Form 8-K Current Report for AudioEye, Inc. covers events occurring on March 24, 2023, with the report filed on March 28, 2023. The filing details corporate governance changes, including the appointment of a new director, amendments to executive compensation, and updates to the Company's By-Laws.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and personnel matters.
Material Changes
- Board Expansion: The Board of Directors increased its size to six members and elected Dr. Katherine E. Fleming as a new director. She is currently the CEO and President of the J. Paul Getty Trust and formerly served as Provost of New York University.
- Committee Assignments: Dr. Fleming was appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, effective at the 2023 Annual Meeting.
- Executive Compensation Amendment: The Company amended the Executive Employment Agreement with Dr. Carr Bettis (Executive Chairman). Effective March 31, 2023, his compensation includes a continued annual cash salary of $36,000 and a monthly award of 772 fully vested shares of common stock.
- Director Compensation Policy Update: Effective April 1, 2023, the non-employee director compensation policy was updated to include specific Restricted Stock Unit (RSU) grants:
- Annual award: 5,667 RSUs per director.
- Lead Independent Director additional annual award: 2,833 RSUs.
- Quarterly award: 667 RSUs per director.
- Committee Chair additional quarterly award: 200 RSUs.
- Lead Independent Director additional quarterly award: 333 RSUs.
- By-Law Amendments: The Board approved amendments to the By-Laws effective March 24, 2023. Key changes include stricter notice requirements for stockholder nominations (90-120 days prior to the anniversary of the preceding year's meeting), requirements for proxy solicitation compliance with Rule 14a-19, and the reservation of white proxy cards for the Board's exclusive use.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to operations or finances are disclosed in this report, other than the standard procedural risks associated with the new By-Law amendments regarding stockholder nominations.
Investor Verification Checklist
- Verify the impact of the new director compensation policy on future share dilution and expense recognition.
- Review the full text of the Second Amendment to Dr. Carr Bettis's employment agreement (Exhibit 10.1) for additional terms not summarized in the filing.
- Confirm the specific dates for the 2023 Annual Meeting to understand the effective dates of Dr. Fleming's committee appointments and the new RSU vesting schedules.
- Assess the implications of the tightened By-Law notice periods for potential stockholder activism or proxy contests.